Patents by Inventor Kenth T. Gustafsson

Kenth T. Gustafsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha (1,3) galactosyl transferase negative swine
    Publication number: 20030014770
    Abstract: Transgenic swine in which the normal expression of &agr;(1,3) galactosyltransferase is prevented in at least one organ of tissue type. The absence or inactivation of this enzyme prevents the production of carbohydrate moieties having the distinctive terminal Gal&agr;1-3Gal&bgr;1-4GlcNAc epitope that is a significant factor in xenogeneic, particularly human, transplant rejection of swine grafts.
    Type: Application
    Filed: March 15, 2002
    Publication date: January 16, 2003
    Applicant: The General Hospital Corporation
    Inventors: Kenth T. Gustafsson, David H. Sachs, Manfred W. Baetscher
  • &agr;(1,3) galactosyltransferase negative porcine cells
    Patent number: 6413769
    Abstract: Transgenic swine in which the normal expression of &agr;(1, 3) galactosyltransferase is prevented in at least one organ of tissue type. The absence or inactivation of this enzyme prevents the production of carbohydrate moieties having the distinctive terminal Gal&agr;1-3Gal&bgr;1-4GlcNAc epitope that is a significant factor in xenogeneic, particularly human, transplant rejection of swine grafts.
    Type: Grant
    Filed: September 15, 1997
    Date of Patent: July 2, 2002
    Assignees: University of London, The General Hospital Corporation
    Inventors: Kenth T. Gustafsson, David H. Sachs, Manfred W. Baetscher
  • .alpha.(1,3) galactosyltransferase negative porcine cells
    Patent number: 6153428
    Abstract: Transgenic swine in which the normal expression of .alpha.(1,3) galactosyltransferase is prevented in at least one organ of tissue type. The absence or inactivation of this enzyme prevents the production of carbohydrate moieties having the distinctive terminal Gal.alpha.1-3Gal.beta.1-4GlcNAc epitope that is a significant factor in xenogeneic, particularly human, transplant rejection of swine grafts.
    Type: Grant
    Filed: March 26, 1996
    Date of Patent: November 28, 2000
    Assignee: BioTransplant, Inc.
    Inventors: Kenth T. Gustafsson, David H. Sachs